Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 10/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.45 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.43 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5799563 | 0.82 | NOTUM (0.58) | NOTUMKDM4ECYP2C19PDK2 | |
| SCHEMBL2552638 | 0.81 | TRIM24 (0.58) | NOTUMKDM4E | |
| SCHEMBL2323342 | 0.80 | ALDH1A1 (0.45) | NOTUMKDM4E | |
| SCHEMBL1573274 | 0.80 | NOTUM (0.83) | NOTUM | |
| SCHEMBL1222301 | 0.79 | NOTUM (0.79) | NOTUMKDM4ECYP2C19 | |
| SCHEMBL5799181 | 0.79 | NOTUM (0.59) | NOTUMCYP2C19PDK2 | |
| SCHEMBL5799166 | 0.79 | NOTUM (0.58) | NOTUMKDM4ECYP2C19PDK2 | |
| SCHEMBL5800964 | 0.79 | NOTUM (0.83) | NOTUMKDM4E | |
| SCHEMBL14507628 | 0.78 | NOTUM (0.57) | NOTUMKDM4ECYP2C19PDK2 | |
| Hydrochloric Acid SCHEMBL6969582 | 0.77 | NOTUM (0.77) | NOTUMKDM4ECYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014810-A1 | Use of substituted 2 phenylbenzimidazoles as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014810-A1 | Use of substituted 2 phenylbenzimidazoles as medicaments | GLP1R, GIPR, GCGR | NOTUM 3388/4885KDM4E 2371/4885CYP2C19 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.